Bega – Earnings Review

Bega recently provided a trading update, with FY22 underlying EBITDA expected to be in the range of
A$195-215mn.

Earnings have been impacted by supply chain-related disruptions, with some offset by the full-year contribution of the Lion Dairy & Drinks acquisition and related cost synergies. FY23 earnings should reaccelerate and recent shareholder support from Andrew Forrest suggests the current price range is a good opportunity to build a position.

Coinbase – Acquires Fairx

Nasdaq-listed crypto exchange operator Coinbase announced Wednesday that it has acquired Fairx, a regulated derivatives trading platform.

Fairx is regulated by the Commodity Futures Trading Commission (CFTC) as a derivatives exchange or Designated Contract Market (DCM).

“Through this acquisition, we plan to bring regulated crypto derivatives to market, initially through Fairx’s existing partner ecosystem,” Coinbase detailed. “Over time, we plan to leverage Fairx’s infrastructure to offer crypto derivatives to all Coinbase customers in the US.”

DexCom – Algo Buy

DexCom is a medical device company that focuses on helping diabetes patients achieve better health outcomes. The company currently generates most of its revenue from its G6 continuous glucose monitoring (CGM) system, which helps those with diabetes keep track of their blood glucose levels.

In the first nine months of 2021, the company’s revenue increased 28.9% to $1.8 billion over the prior-year period while net income jumped 25.8% to $174.1 million.

Snap – Algo Buy

{SNAP.NYS} is under Algo Engine buy conditions. The correction in high PE technology and the negative impact to earnings from the change in Apple’s advertising privacy regulations have seen Snap correct from $80 down to $38. Even after the 50% correction, Snap remains on 80x PE.

Despite the still high PE ratio, Snap offers tremendous growth and we’re accumulating the stock within our defined range.